CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

Shenyang Northern Hospital1,029 enrolled

Overview

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.

Study Type

OBSERVATIONAL

Enrollment

1,029

Conditions

ACS Clonal Hematopoiesis of Indeterminate Potential Smoking Cessation

Interventions

clonal hematopoiesis of indeterminate potential

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. In-patients with acute coronary syndrome to undergo PCI 2. Complete revascularization during the index hospitalization 3. Written informed consent Exclusion Criteria: * 1\. Periprocedural complications (coronary artery dissection, perforation, myocardial infarction, stroke, death) 2. Planned coronary revascularization at discharge 3. Patients with severe chronic disease (uremia, liver cirrhosis, COPD (chronic obstructive pulmonary disease) 4. Abnormal blood counts caused by hematological diseases 5. Diagnosed malignancy

Outcomes

Primary Outcomes

prevalence of CHIP mutations

Whole-exome sequencing is performed to detect the presence of CHIP mutations

Time frame: 24 hours

Secondary Outcomes

MACCE

MACCE includes cardiac death, non-fatal MI, non-fatal stroke, rehospitalization due to heart failure, ischemia-driven revascularization at 12 months

Time frame: 1 year